20 June, 2017
Closing price generally refers to the last price at which a stock trades during a regular trading session.
RDUS has been the subject of several recent research reports. Jefferies Group LLC restated a "hold" rating and issued a $40.00 target price on shares of Radius Health in a report on Friday, February 24th.
News stories about Radius Health (NASDAQ:RDUS) have trended positive this week, according to Alpha One Sentiment Analysis. The stock's 50 day moving average price is $36.71 and its 200 day moving average price is $40.48.
Amid volatile financial markets and the presidential election, various investment brokerages have made amendments to their price targets and ratings on shares of Radius Health, Inc. Canaccord Genuity set a $85.00 target price on Radius Health and gave the stock a "buy" rating in a report on Saturday, February 25th.
Investors and Traders continue to monitor technical levels of shares of Radius Health, Inc. The Congress Asset Management Company holds 248,714 shares with $13.31M value, down from 274,723 last quarter.
ATR value of company was 1.71. Since the start of the session, the stock has topped out with a high of 35.61 and bottomed with a low of 34.62. They now have a Dollars 70 price target on the stock. H.C. Wainwright maintained Radius Health Inc (NASDAQ:RDUS) on Wednesday, September 21 with "Buy" rating. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.18) by $0.14. State Street Corp now owns 1,885,161 shares of the biopharmaceutical company's stock valued at $71,694,000 after buying an additional 699,023 shares during the last quarter.
08/04/2016 - Radius Health, Inc. was downgraded to "sell" by analysts at Maxim Group. Goldman Sachs initiated the shares of RDUS in report on Wednesday, March 30 with "Neutral" rating.
ILLEGAL ACTIVITY WARNING: This news story was originally published by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally stolen and republished in violation of worldwide copyright & trademark law. (NASDAQ:RDUS) by some 5,421,452 shares, 78 decreased positions by 4,829,699 and 25 held positions by 33,458,703. Cowen & Co upgraded the stock to "Outperform" rating in Thursday, December 15 report.
Emera Incorporated is an energy and services company, which invests in electricity generation, transmission and distribution, gas transmission and utility services. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. BIOTECH GROWTH N V bought $1.80M worth of stock or 50,000 shares. Following the completion of the acquisition, the insider now directly owns 4,890,799 shares of the company's stock, valued at $163,548,318.56. The disclosure for this purchase can be found here. Creative Planning now owns 16,685 shares of the biopharmaceutical company's stock valued at $645,000 after buying an additional 1,720 shares during the period. BB Biotech AG increased its stake in Radius Health by 4.1% in the first quarter. After $-1.32 actual earnings per share reported by Radius Health Inc for the previous quarter, Wall Street now forecasts 0.76 % negative EPS growth. Cantor Fitzgerald maintained Radius Health Inc (NASDAQ:RDUS) rating on Sunday, June 4. Moreover, Rock Springs Capital Management Lp has 2.32% invested in the company for 910,250 shares. Radius Health earned a daily sentiment score of 0.48 on Alpha One's scale. The 10% Owner added these shares by way of transaction on May. Finally, BlackRock Fund Advisors increased its stake in shares of Radius Health by 5.5% in the third quarter. 20,557 are owned by Blackrock Gru Limited.
Fmr Llc owns $214.67 million in Radius Health, Inc., which represents roughly 11.86% of the company's market cap and approximately 12.44% of the institutional ownership. The Firm is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis.